Irvine, California and Amsterdam (ots/PRNewswire) - Agendia, an innovative molecular cancer diagnostics company, today announced that the company successfully completed a recent, routine inspection of its Irvine, California-based laboratories by the US Food and Drug Administration (FDA). Agendia received FDA 510(k) clearance for its MammaPrint(R) breast cancer recurrence test in early 2007. It remains the first and only ...
Florence, Italy (ots/PRNewswire) - Cognitive impairment in multiple sclerosis is expressed in the clinical course of the disease in 43-70% of cases. It affects 1/3rd of school-aged patients The leading international experts in the field of neurological research for multiple sclerosis gathered in Florence for the ...
International Society for Cellular Therapy
Vancouver (ots/PRNewswire) - The interest of many insured US citizens was represented by participation of payor organizations including Anthem Blue Cross Blue Shield, LifeTrac and OptumHealth. In keeping with its mission to drive the commercialization of cell therapy products and advance global patient access, ISCT ...
St. Gallen, Switzerland (ots) - ForaCare Suisse AG located in St. Gallen, Switzerland announced today the launch of a Bluetooth enabled innovative, smart single-unit devices for combined blood glucose and blood pressure (BP) monitoring. One device, the Comfort Pro GD 40, is approved for use by medical professionals and the other, Duo Ultima D40b, is being made ...
Bayer HealthCare Pharmaceuticals
London (ots/PRNewswire) - - Young People Report High Levels of Unprotected Sex and Barriers Affecting Their Right to Obtain Trustworthy Information About Sex and Contraception Key survey results - Since 2009 the number of people having sex without contraception with a new partner has increased by - 111% in France ...
New York and Stockholm (ots/PRNewswire) - March 2011 Data Confirm Strong Treatment Effect of Chemosaturation Delcath Systems announced today that James F. Pingpank, MD, FACS, Associate Professor of Surgery at the University of Pittsburgh School of Medicine, will present updated investigator results from the Phase 3 ...
Takeda Pharmaceutical Company Limited
London and Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited (Takeda) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for EdarbiTM (azilsartan medoxomil, development code: TAK-491), a new ...
Cambridge, England (ots/PRNewswire) - New research demonstrates oxycodone/naloxone prolonged-release tablets superiority compared with oxycodone prolonged-release tablets[1] Treatment with Targin(R)(oxycodone/naloxone) prolonged-release tablets provides superior bowel function without compromising analgesic efficacy ...
Lyon, France (ots/PRNewswire) - - Vaccine strain used in the production of oral polio vaccines against type 3 poliovirus - Sanofi Pasteur, the vaccines division of Sanofi , announced today it is donating to the World Health Organization (WHO) a vaccine strain used for polio eradication. The biological material given by Sanofi Pasteur is the original viral seed used to ...
Irvine, California and Amsterdam (ots/PRNewswire) - - Peer-Reviewed Article Notes That Multi-Gene Subtyping Profile Provides Deeper Insight Into Breast Cancer Agendia, an innovative molecular cancer diagnostics company, today announced that a published report highlighting the development and validation of its 80-gene BluePrint breast cancer profile was published online ...
http://resources.euroadhoc.com/us/0uYGlcN6 issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
http://resources.euroadhoc.com/us/1HCW6Rjz http://resources.euroadhoc.com/us/IBzY8Led issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 ...
issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: Open Market / XETRA: Frankfurt, free trade: Berlin, Main Standard: SIX Swiss Exchange language: English ...
Amsterdam, The Netherlands (ots) - New data presented at the 14th World Conference on Lung Cancer in Amsterdam, The Netherlands, show the efficacy of the 2nd generation 5-HT3 receptor antagonist alone and in combination with aprepitant New data on the 2nd generation 5-HT3 receptor antagonist palonosetron, in the ...
European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)
Prague (ots) - The SHARP-study has shown that lowering LDL cholesterol with ezetimibe/simvastatin leads to a significant reduction in major atherosclerotic events among CKD-patients. Whether it also has a favourable effect on renal disease progression was another of the issues addressed by the SHARP study [abstract ...
European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)
Prague, Czech Republic (ots) - The randomised, double-blind, placebo-controlled multi-centre study (abstract no. 2511) investigated the efficacy and safety of the monoclonal antibody rituximab (RTX) in 197 ANCA-associated vasculitis (AAV) patients. This study showed that in patients with severe AAV a single course ...
issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: ...
issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: Open Market / XETRA: Frankfurt, free trade: Berlin, Main Standard: SIX Swiss Exchange language: English Contact: Sensus Investor & Public Relations, Zurich: Tel +41 43 366 55 ...
Contact: Kobi Ben Efraim, Chief Financial Officer, LifeWatch AG; Tel +41 52 632 00 50 | Fax +41 52 632 00 51 | E-mail kobibe@lifewatch.com Sensus Investor & Public Relations, Zürich; Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | E-mail lifewatch@sensus.ch Branche: Healthcare Providers ISIN: ...
Lugano, Switzerland/Sandpoint, ID (ots) - Helsinn Group makes an equity investment for a minority interest in Thorne Research, Inc. and plans to jointly commercialize nutritional supplement products with initial focus on meeting the needs of people living with cancer Helsinn Group a rapidly growing pharmaceutical ...
Contact: Sensus Investor and Public Relations GmbH, Zürich: Tel +41 43 366 55 11 | Fax +41 43 366 55 12 Email lifewatch@sensus.ch Branche: Healthcare Providers ISIN: CH0012815459 WKN: 1281545 Index: SPI, SPIEX Börsen: Frankfurt / Open Market / XETRA Berlin / free trade SIX Swiss Exchange / Main Standard ...
Contact: Sensus Investor and Public Relations GmbH, Zürich: Tel +41 43 366 55 11 | Fax +41 43 366 55 12 Email lifewatch@sensus.ch Branche: Healthcare Providers ISIN: CH0012815459 WKN: 1281545 Index: SPI, SPIEX Börsen: Frankfurt / Open Market / ...
Contact: Sensus Investor and Public Relations, Zürich: Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | Email lifewatch@sensus.ch Branche: Healthcare Providers ISIN: CH0012815459 WKN: 1281545 Index: SPI, SPIEX Börsen: Frankfurt / Open Market / XETRA Berlin / free trade SIX Swiss Exchange / Main Standard ...
Contact: Kobi Ben Efraim, Chief Financial Officer, LifeWatch AG: Tel +41 52 632 00 50 | Fax +41 52 632 00 51; Email kobibe@lifewatch.com Sensus Investor and Public Relations GmbH, Zürich: Tel +41 43 366 55 11 | Fax +41 43 366 55 12; Email lifewatch@sensus.ch Branche: Healthcare Providers ISIN: CH0012815459 WKN: 1281545 Index: SPI, SPIEX Börsen: Frankfurt / Open Market / XETRA Berlin / free trade SIX Swiss Exchange / ...
Contact: Sensus Investor & Public Relations, Zürich: Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | E-mail lifewatch@sensus.ch Branche: Healthcare Providers ISIN: CH0012815459 WKN: 1281545 Index: SPI, SPIEX Börsen: Frankfurt / Open Market / XETRA Berlin / free trade SIX Swiss Exchange / Main Standard ...
Contact: Sensus Investor & Public Relations, Zürich: Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | E-mail: lifewatch@sensus.ch Branche: Healthcare Providers ISIN: CH0012815459 WKN: 1281545 Index: SPI, SPIEX Börsen: Frankfurt / Open Market / XETRA Berlin / free trade SIX Swiss Exchange / Main Standard ...
Freising, Germany (ots) - Pieris AG announced today the upcoming presentation of new preclinical and interim Phase I clinical trial data for its PRS-050 Anticalin( program, currently under evaluation for the treatment of cancer. Dr. Laurent Audoly, Chief Scientific Officer of Pieris, will speak on Friday, February ...
Contact: Woo Kim, Senior Vice President of Strategy and Business Development, LifeWatch Tel +1 847 813 4299 | Fax +1 847 813 2448 | E-mail: wkim@lifewatch.com Sensus Investor & Public Relations, Zürich: Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Company Information/LifeWatch AG 09.02.2011 Neuhausen am Rheinfall/Switzerland - ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Company Information/Capital reduction 02.02.2011 Neuhausen am Rheinfall / ...